Acidity Pills: CDSCO Restricts Key Gastro Drugs to Prescription-Only as Major Trials Advance

In a major regulatory clampdown aimed at curbing the unchecked culture of self-medication in India, the country’s apex drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has mandated that pharmacies cannot dispense key advanced gastrointestinal medications without a validated medical prescription. The directive focuses on modern acidity and reflux formulations—specifically Vonoprazan—restricting counter sales to prevent long-term micronutrient deficiencies and obscure underlying digestive pathologies. Alongside tightening retail curbs, the regulatory body reviewed crucial clinical trial protocols for breakthrough therapies targeting fatty liver disease (NASH/MASH), irritable bowel syndrome with constipation (IBS-C), and pediatric sickle cell disease.

Strict Curb on Vonoprazan: Why Over-the-Counter Sales Are Being Halted

The regulatory intervention targets widespread unmonitored use of potassium-competitive acid blockers (P-CABs) across retail chemists:

• Prescription Mandate for 10 mg and 20 mg Strengths: Approved in India in 10 mg and 20 mg formulations, Vonoprazan provides potent, rapid gastric acid suppression; however, chemists must now strictly require a licensed physician’s prescription prior to dispensing.

• Risks of Unchecked Chronic Consumption: CDSCO cautioned that prolonged, habitual intake of high-potency acid reducers masks serious gastrointestinal conditions while precipitating systemic nutritional issues, such as severe Vitamin B12 and magnesium deficiencies, bone density reduction, and altered gut microbiomes.

• Underlying Root-Cause Diagnosis: Health authorities emphasize that recurring heartburn and acid reflux warrant clinical workups to rule out peptic ulcers, gastroesophageal reflux disease (GERD), or chronic gastritis rather than reliance on quick over-the-counter fixes.

Breakthrough Phase 3 Trials for Fatty Liver: Efruxifirmin and Resmetirom

The drug authority also evaluated advanced trial pathways for next-generation metabolic and hepatic therapies:

• Efruxifirmin Phase 3 Evaluation: Clinical trials for Efruxifirmin are advancing to assess its efficacy in treating non-alcoholic steatohepatitis (NASH), specifically targeting patients suffering from excessive liver fat accumulation combined with chronic hepatic inflammation and progressive scarring.

• Dosing Protocols for Resmetirom: Phase 3 trials involving various dosage tiers of Resmetirom are underway, analyzing whether thyroid hormone receptor-beta (THR-β) agonists can safely resolve steatohepatitis and reverse liver fibrosis.

• Evaluating Safety and Efficacy: The clinical objective across both investigational drugs is to establish long-term liver safety profiles and reduce cardiovascular and cirrhosis risks in high-risk metabolic patients.

Modern Solutions for IBS-C and Expanding Pediatric Trials for Sickle Cell

The committee reviewed clinical protocols for severe bowel disorders and genetic blood conditions:

• Linaclotide for Chronic Constipation and IBS-C: Patients battling irritable bowel syndrome with constipation (IBS-C) alongside persistent abdominal cramping are being evaluated under structured Linaclotide regimens, with recommended 72 mcg and 145 mcg doses for chronic idiopathic constipation, while a higher 290 mcg dosage demonstrates significant symptom relief for severe IBS-C pain.

• Atavopivat Trials for Children with Sickle Cell: For sickle cell disease, experimental therapeutic Atavopivat is entering Phase 3 trial evaluations expanded to include pediatric patients aged 6 to 12 years.

• Protecting Vulnerable Age Groups: Regulators emphasized that until comprehensive clinical endpoints demonstrate pediatric efficacy and long-term tolerability, Atavopivat cannot be adopted as standard pediatric therapy, reinforcing that experimental access must strictly proceed under monitored clinical trial protocols.